Atara Biotherapeutics

Pascal Touchon, President and CEO
San Francisco, CA

Virtual Presentation
Atara Biotherapeutics is a leading allogeneic T cell immunotherapy company leveraging its novel allogeneic Epstein Barr virus (EPV) T cell platform to develop transformative therapies for patients with cancer and autoimmune diseases. Atara’s pipeline includes tabelecleucel in Phase III development for EBV-driven post-transplant lymphoproliferative disease and in earlier stages of development for other EBV-associated diseases, ATA188 for multiple sclerosis, and next-generation CAR T therapies for solid tumors and hematologic cancers.

By using this website you agree to accept our Privacy Policy and Terms & Conditions